Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xynomic Acquires Boehringer Cancer Candidate in $800 Million Deal

publication date: Dec 20, 2018

Xynomic Pharma, a US-China oncology company, has acquired a worldwide license to an mTORC1/2 inhibitor developed by Boehringer Ingelheim in exchange for an $800 million package of upfront, milestone and royalty payments. BI has completed a successful Phase I trial of BI 860585. In 2019, Xynomic plans to start two clinical trials of the molecule: a potentially pivotal Phase II trial combining BI 860585 with a standard-of-care treatment against breast cancer, and a Phase Ib trial in combination with Xynomic's RAF inhibitor as a colorectal cancer treatment. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital